Xu L, Chen L, Zhang W. Neoadjuvant treatment strategies for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(12): 1550-1566 [PMID: 35070063 DOI: 10.4240/wjgs.v13.i12.1550]
Corresponding Author of This Article
Wei Zhang, MD, Assistant Professor, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jie Fang Avenue, Wuhan 430030, Hubei Province, China. weizhangtjh@hust.edu.cn
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Dec 27, 2021; 13(12): 1550-1566 Published online Dec 27, 2021. doi: 10.4240/wjgs.v13.i12.1550
Neoadjuvant treatment strategies for hepatocellular carcinoma
Lei Xu, Lin Chen, Wei Zhang
Lei Xu, Lin Chen, Wei Zhang, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Author contributions: Xu L wrote the paper; Chen L revised the manuscript; Zhang W proposed the topic and finalized this review.
Supported byNational Natural Science Foundation of China, No. 81860117.
Conflict-of-interest statement: The authors declare no conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei Zhang, MD, Assistant Professor, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jie Fang Avenue, Wuhan 430030, Hubei Province, China. weizhangtjh@hust.edu.cn
Received: April 19, 2021 Peer-review started: April 19, 2021 First decision: June 13, 2021 Revised: June 27, 2021 Accepted: November 30, 2021 Article in press: November 30, 2021 Published online: December 27, 2021 Processing time: 248 Days and 11.7 Hours
Abstract
The incidence of hepatocellular carcinoma (HCC) remains high globally. Surgical treatment is the best treatment for improving the prognosis of patients with HCC. Neoadjuvant therapy plays a key role in preventing tumor progression and even downstaging HCC. The liver transplantation rate and resectability rate have increased for neoadjuvant therapy. Neoadjuvant therapy is effective in different stages of HCC. In this review, we summarized the definition, methods, effects, indications and contraindications of neoadjuvant therapy in HCC, which have significance for guiding treatment.
Core Tip: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. A considerable number of patients cannot receive radical therapy due to advanced HCC at the first diagnosis, leading to a poor prognosis. Neoadjuvant treatment enables more patients with HCC inside or outside the Milan criteria to receive surgical treatment, such as partial liver resection and liver transplantation. In this study, we reviewed the current status of neoadjuvant therapy in HCC.
